STOCK TITAN

Caribou Biosciences (CRBU) Stock News, Sep 2023-Mar 2024

CRBU NASDAQ

Caribou Biosciences develops CRISPR genome-edited, allogeneic CAR-T cell therapies for hematologic malignancies. Company updates center on vispacabtagene regedleucel, or vispa-cel, an anti-CD19 CAR-T therapy being evaluated in B cell non-Hodgkin lymphoma and large B cell lymphoma, and CB-011, an anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma.

Recurring announcements include clinical and translational data from the ANTLER and CaMMouflage trials, FDA designations and trial-design interactions, financial results, research and development spending, cash resources, pipeline prioritization, and medical or investor conference participation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.47%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
conferences clinical trial
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.09%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.11%
Tags
management
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.35%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
management

FAQ

What is the current stock price of Caribou Biosciences (CRBU)?

Caribou Biosciences (CRBU) last closed at $0.2843.

What is the market cap of Caribou Biosciences (CRBU)?

The market cap of Caribou Biosciences (CRBU) is approximately $30.7M.